Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.004 | 0.5 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.004 | 0.5 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.004 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.004 | 0.5 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.004 | 0.5 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.004 | 0.5 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.004 | 0.5 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.004 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.